<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02878863</url>
  </required_header>
  <id_info>
    <org_study_id>AIH-1</org_study_id>
    <nct_id>NCT02878863</nct_id>
  </id_info>
  <brief_title>Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis</brief_title>
  <official_title>Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Treatment of Auto-immune Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiaoli Fan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label,prospective, randomized pilot study to evaluate the efficacy, safety and
      tolerability of paeoniflorin, for the treatment of autoimmune hepatitis (AIH) with mild
      necroinflammatory activity on liver biopsy.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients that achieve biochemical remission of AIH</measure>
    <time_frame>Month 6 during treatment with paeoniflorin combination of hepatoprotective drugs or hepatoprotective drugs only</time_frame>
    <description>Biochemical remission is defined as alanine transaminase(ALT),aspartate transaminase(AST) and immunoglobulin G(IgG) within normal limits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alanine transaminase (ALT)</measure>
    <time_frame>Month 1, 3, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate transaminase(AST)</measure>
    <time_frame>Month 1, 3, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin G(IgG)</measure>
    <time_frame>Month 1, 3, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Globin(GLB)</measure>
    <time_frame>Month 1, 3, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total bilirubin(TB)</measure>
    <time_frame>Month 1, 3, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct bilirubin(DB)</measure>
    <time_frame>Month 1, 3, 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatitis, Autoimmune</condition>
  <arm_group>
    <arm_group_label>Paeoniflorin + phosphatidylcholine or silymarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paeoniflorin tablets(600mg, tid)combination of phosphatidylcholine or silymarin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phosphatidylcholine or silymarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phosphatidylcholine or silymarin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paeoniflorin + phosphatidylcholine or silymarin</intervention_name>
    <arm_group_label>Paeoniflorin + phosphatidylcholine or silymarin</arm_group_label>
    <other_name>total glucosides of paeony(TGP)+ phosphatidylcholine or silymarin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phosphatidylcholine or silymarin</intervention_name>
    <arm_group_label>Phosphatidylcholine or silymarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 20-70 years;

          -  Diagnosed with AIH or primary biliary cirrhosis-autoimmune hepatitis overlap syndrome
             based on liver biopsy results and without indication of immunosuppressive therapy;

          -  High levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST)(1-3
             X ULN);

               -  High levels of IgG(1-1.5 X ULN);

               -  Liver biopsy showed mild lymphocytic piecemeal necrosis (interface hepatitis);

               -  Agreed to participate in the trial, and assigned informed consent.

        Exclusion Criteria:

          -  The presence of hepatitis A, B, C, D, or E virus infection;

          -  Patients with presence of liver cirrhosis or portal hypertension;

          -  Patients with presence of fulminant liver failure;

          -  Primary sclerosing cholangitis, non-alcoholic steatohepatitis, drug induced liver
             disease or Wilson disease confirmed by liver biopsy;

          -  Pregnant and breeding women;

          -  Severe disorders of other vital organs, such as severe heart failure, cancer;

          -  Parenteral administration of blood or blood products within 6 months before screening;

          -  Recent treatment with drugs having known liver toxicity;

          -  Taken part in other clinic trials within 6 months before screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Yang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>West China Hospital,Chengdu, Sichuan, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Xiaoli Fan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silymarin</mesh_term>
    <mesh_term>Peoniflorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

